Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
PLN 80
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of BCX.WA is 133 and suggests 66% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Data is available to registered users only
Buy
Sell